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ABSTRACT
Objective: To assess the cost-effectiveness of duloxetine compared with
conservative therapy in women with stress urinary incontinence (SUI).
Methods: Cost and outcome data were taken from the Stress Urinary
Incontinence Treatment (SUIT) study, a 12-month, prospective, observa-
tional, naturalistic, multicenter, multicountry study. Costs were assessed in
UK £ and outcomes in quality adjusted life years using responses to the
EuroQol (EQ-5D); numbers of urine leaks were also estimated. Potential
selection bias was countered using multivariate regression and propensity
score analysis.
Results: Duloxetine alone, duloxetine in combination with conservative
treatment, and conservative treatment alone were associated with roughly
two fewer leaks per week compared with no treatment. Duloxetine alone
and with conservative treatment for SUI were associated with incremental
quality-adjusted life-years (QALYs) of about 0.03 over a year compared
with no treatment or with conservative treatment alone. Conservative
treatment alone did not show an effect on QALYs. None of the interven-
tions appeared to have marked impacts on costs over a year. Depending on
the form of matching, duloxetine either dominated or had an incremental
cost-effectiveness ratio (ICER) below £900 per QALY gained compared
with no treatment and with conservative treatment alone. Duloxetine plus
conservative therapy had an ICER below £5500 compared with no treat-
ment or conservative treatment alone. Duloxetine compared with dulox-
etine plus conservative therapy showed similar outcomes but an additional
cost for the combined intervention.
Conclusions: Although the limitations of the use of SUIT’s observational
data for this purpose need to be acknowledged, the study suggests that
initiating duloxetine therapy in SUI is a cost-effective treatment
alternative.
Keywords: cost-effectiveness analysis, EQ-5D, observational study, out-
comes research, women’s health.
Introduction
Urinary incontinence (UI), or the “involuntary leakage of urine”
[1], affects between 10% and 60% of women worldwide [2–6].
The condition can be categorized into stress urinary incontinence
(SUI), which is involuntary leakage of urine on exertion, sneez-
ing, or coughing; or urge urinary incontinence (UUI), which is
involuntary leakage of urine accompanied by, or immediately
preceded by, urgency. Both symptoms are present in mixed
urinary incontinence (MUI) [1]. SUI accounts for approximately
half of all urinary incontinence in adult women [2,3,5].
Initial management of SUI is recommended in general prac-
tice using conservative treatments, including lifestyle interven-
tions and pelvic ﬂoor muscle training (PFMT) [7]. The
Prospective Urinary Incontinence Research study (PURE) was a
European observational study to investigate the economic and
social impact of UI [8]. PURE baseline data showed that
25–40% of women with symptoms of SUI were receiving medi-
cations which in Europe were unlicensed for the treatment of
SUI, including alpha-adrenergic agonists, tricyclic antidepres-
sants (TCA), and estrogens [9]. These drugs show limited evi-
dence of efﬁcacy in SUI, and some have side effects (e.g.,
hypertension, arrhythmias, abnormal vaginal bleeding, and
breast cancer) [10]. Duloxetine has been evaluated as a treat-
ment for SUI in a number of large, multinational randomized
clinical trials, and is the ﬁrst drug approved in Europe to treat
moderate to severe SUI. A recent systematic review of nine ran-
domized trials of duloxetine in SUI concluded that compared
with placebo or no treatment, duloxetine improved health-
related quality of life but commented on the common side
effect of nausea [11]. Decision analytic modeling studies relat-
ing to the UK and Dutch health-care systems have used a trial
and other evidence to assess the cost-effectiveness of duloxetine,
but have commented on the considerable uncertainty in existing
evidence [12,13].
The Stress Urinary Incontinence Treatment (SUIT) study
was a 12-month, prospective, observational, naturalistic, mul-
ticenter, multicountry study designed to evaluate the cost-
effectiveness of duloxetine compared with other forms of
nonsurgical intervention in the treatment of women with symp-
toms of SUI [14]. The study included patients in Germany,
United Kingdom, Sweden, and Ireland, with enrolment at the
time of initiation of or change in SUI treatment. The partici-
pating physician, at his/her own discretion, and in consultation
with the patient, determined the treatment initiation or change.
Participating investigators observed and recorded data on a
regular basis. Data were collected during visits at baseline
(observation 1) and at 3 (observation 2), 6 (observation 3), and
12 (observation 4) months after baseline, plus or minus 6
weeks. The article reports on the primary objective of the SUIT
study, which was to assess the cost-effectiveness of duloxetine
using data from SUIT.
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Methods
Overview
The purpose of this analysis was to study the cost-effectiveness of
initiating duloxetine for treatment of SUI against non-surgical
therapies. Cost-effectiveness was assessed in terms of the differ-
ential costs and quality-adjusted life-years (QALYs) between the
SUI interventions observed during the 12 months of the study.
Costs were assessed from the perspective of the health-care
system plus costs to patients of protective materials, based on UK
unit costs. The average number of leaks during the last 7 days
reported at observation 4 was used to validate treatment effect on
health related quality of life (HRQoL). Given the observational
nature of the SUIT study, statistical methods were used to address
the potential for selection bias accompanying a nonrandomized
design.
Deﬁning the Cohort for Analysis
In order to avoid the effects of prior treatments on SUI outcomes
and to identify as homogeneous a group as possible, a speciﬁc
cohort was deﬁned for the analysis. Only study participants that
were 1) not undergoing any treatment for SUI at observation 1;
and 2) at observation 2 were reported to be undergoing one of
the following four treatments: 2.a) duloxetine alone; 2.b) dulox-
etine plus conservative treatment for SUI; 2.c) conservative treat-
ment for SUI; or 2.d) no treatment for SUI were included.
Patients on other pharmaceutical treatments for SUI (n = 122)
were omitted from the analysis cohort given the variety of drugs
taken (including in combination) and the small numbers
involved. The latter also explains why patients undergoing sur-
gical treatments were excluded (n = 31).
Switches of treatments at observation 3 and observation 4
were observed and recorded in SUIT. Signiﬁcant switches to
alternative treatments were observed in the treatment cohorts
studied between observation 2 and observation 4, ranging from
24% in “conservative treatment alone” to 45% in the “no treat-
ment for SUI” cohort at observation 2. Therefore, the cost-
effectiveness analysis evaluated the cost-effectiveness of
treatment strategies of initiating patients not treated at the pre-
vious visit for SUI to 1) duloxetine alone; 2) duloxetine plus
conservative treatment for SUI; 3) conservative treatment for
SUI; and 4) no treatment for SUI.
Missing Data
Some missing study visits as well as missing individual data
entries were observed in the study. One hundred eighty patients
(11.9% of the analysis cohort) missed their visit 3, and 207
(13.7%) visit 4. Although the missing data on individual param-
eters seem minimal, if all patients with any missing data were
excluded from the estimation, nearly a third of the study cohort
would have been lost in some of the analyses. Therefore, a
multivariate multiple imputation framework was developed,
using the ICE program in Stata [15], to impute missing baseline
characteristics, as well as missing outcome data, in a way that
allowed for the estimates to account for the fact that part of data
was imputed. The framework was used to impute both health
outcomes and costs for SUI, as information from all visits was
used to impute the missing data points. Five datasets were gen-
erated by imputing the missing data points. All analyses were
processed on each of these datasets, and the results combined
using Rubin’s rules for combining the within-dataset and
between-datasets variances [15].
Health Outcomes
EQ-5D [16] data were collected from SUIT participants at each
study visit. The instrument has ﬁve domains (mobility, self care,
usual activities, pain, depression/anxiety), each of which has
three response variables (no problems, moderate problems and
severe problems). Patients’ responses to these domains locate
them into one of 243 theoretically possible health states (245
with “dead” and “unconscious”). These EQ-5D states, together
with a set of values (or utilities) on a zero (death) to one (full
health) scale for these states from a general UK population [17],
were used to evaluate HRQoL of study participants at baseline,
at 3 months (observation 2), at 6 months (observation 3), and at
1 year (observation 4). Area under the curve methods [18],
together with linear interpolation of utilities between the study
visits, were used to estimate QALYs over the 1-year study period.
Where patients’ responses to EQ-5D domains were missing and
imputed, the QALYs were reestimated following the imputation.
Resource Use and Costs
Five elements of resource use were measured directly in the study
using case record forms: 1) visits to health-care professionals; 2)
diagnostic procedures for UI; 3) pharmacologic treatments for
SUI; 4) conservative treatment for SUI; and 5) protective material
for UI.
Although SUIT was a multinational study, decisions about the
use of medical technologies are taken at national level. Therefore,
the current analysis was developed from the perspective of the
UK NHS. Unit costs were taken, where available, from routine
UK sources inﬂated to 2007 prices, where needed, using the
Hospital and Community Health Services (HCHS) pay and price
inﬂation [19]. The key unit costs used in the analysis, together
with their sources, are shown in Appendix 1 found at: http://
www.ispor.org/Publications/value/ViHsupplementary/ViH13i5_
Mihaylova.asp. Costs were evaluated over the duration of the
study of about one year.
Statistical Analysis
Two approaches were employed to evaluate treatment effects on
costs and outcomes in a way that would address the possibility of
selection bias: multivariate regression and propensity score
matching.
In the multivariate adjustment approach, outcomes and costs
were modeled as functions of treatment allocation and observed
baseline characteristics in a linear regression modeling frame-
work. The main assumption was that outcomes are independent
of treatment selection after conditioning on the observed factors
within the modeling framework selected. A stepwise backward
elimination algorithm (at 0.05 level of statistical signiﬁcance)
with addition to model (at 0.049 level of statistical signiﬁcance if
subsequently proven important) was used to identify covariates
signiﬁcant at 5% for each of the ﬁve imputed datasets. This was
followed by using all identiﬁed important covariates within a
framework combining regression results over the ﬁve datasets,
and subsequently excluding covariates that were not statistically
signiﬁcant based on a backward elimination algorithm. Treat-
ment cohort indicators (as per observation 2) were kept in the
model even if not statistically signiﬁcant at 5%. The full list of
factors used in the initial models was based on discussion with
clinical coauthors and included baseline EQ-5D, average number
of leaks at baseline, a range of comorbidities, previous surgery
for UI, age, and body mass index. Country of treatment was also
introduced into the regression, and interactions between country
and treatment cohorts were studied. A seemingly unrelated
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regression [20] was undertaken to account for the correlation
between the QALYs and costs at 1 years.
In the propensity score analysis, for each treatment compari-
son, the probability of treatments (propensity scores) were evalu-
ated as a function of observed covariates [21,22]. For each
comparison, patients in the two treatment cohorts were then
matched based on these propensity scores in order to adjust for
observed imbalances and to enable comparison across the
matched patient strata. Comparison of outcomes between treat-
ments was performed after employing three alternative propen-
sity scores matching algorithms: nearest neighbor, Kernel
matching, and stratiﬁcation [23]. The three methods of matching
apply different trade-offs between the quality and the quantity of
the matches, and none of them is a priori superior to the others.
Therefore, a degree of robustness can be achieved by considering
them jointly for the purpose of interpreting the results.
Cost-Effectiveness
Cost-effectiveness was evaluated using the incremental cost-
effectiveness ratio (ICER), which shows the incremental cost per
additional QALY gained from one treatment compared with
another. The constraints of the propensity scores implementation
means that it was not possible to simultaneously compare all
available treatments in the same matched cohort, so a series of
pairwise comparisons was undertaken. Reﬂecting the joint uncer-
tainty in costs and outcomes, the probability that a given inter-
vention is more cost-effective than its comparator is presented
based on the propensity score analysis. This uses a cost-
effectiveness threshold of £20,000 per QALY gained, based on
the lower range of the National Institute of Health and Clinical
Excellence’s stated threshold [24].
Results
Analysis Cohort
A total of 1973 (53%) out of 3739 women participating in SUIT
were not on treatment for their SUI at observation 1. Of these,
1541 were in one of the alternative treatment cohorts of interest.
After excluding participants that received a surgical procedure
for their UI during the study (n = 31), a cohort of 1510 SUIT
participants remained, on whom cost-effectiveness analyses were
based. All of these patients attended their 3-month study visit
and 1330 of them attended their 6-month study visit, while 1303
attended their 1-year visit.
Table 1 outlines the main baseline characteristics by cohort
and overall. The treatment cohorts at observation 2 were used to
compare outcomes of different treatments for SUI. It should be
noted that although all women in SUIT had symptoms of SUI,
only about 40% had pure SUI symptoms, with the rest reporting
symptoms of both stress and urge urinary incontinence.
The demographic characteristics of this cohort were largely
similar to those of the full study population [25], with several
notable differences. Speciﬁcally, the analysis cohort was more
likely to be diagnosed with pure SUI (43% vs. 37.2%).
Resource Use and Costs
Details of the resource use measured in SUIT are pro-
vided in Appendix 2 at: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH13i5_ Mihaylova.asp. To some extent,
the pattern of resource use varied between countries. For
example, in terms of visits to clinical professionals, in the United
Kingdom and Ireland, most women visited their primary care
doctor and relatively few visited a hospital-based physician. This Ta
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position was reversed in Germany and Sweden. Furthermore,
fewer women in the UK received diagnostic tests than those in
other countries. In terms of treatments used to manage SUI, the
proportions of women that underwent pharmacologic treatments
varied from 37% in the United Kingdom to 65% in Germany,
with most of these patients having taken duloxetine, which had
the longest mean duration of use of 258 days over the year. The
proportions of women that received conservative treatments
ranged from 66% in Germany to 94% in Ireland, with 88% in
the United Kingdom. For most women, this took the form of
self-administered pelvic ﬂoor exercises.
Table 2 summarizes the average costs (SD) by treatment
cohort and has not been adjusted for covariates. Average costs
were largest in the duloxetine plus conservative therapy group,
followed by the duloxetine alone group, while the costs in the
conservative treatment group were lower. This observation
could be because of the fact that most patients in the duloxet-
ine cohorts were located in Germany, where the costs of
resource use of health care for SUI were higher, or that patients
in the duloxetine cohorts seemed to have somewhat more
severe symptoms (Table 1). Therefore, without statistically
adjusting for factors determining costs independently of inter-
ventions, it is difﬁcult to determine the effects of treatment
strategies on costs.
Multivariate Regression
The results of the regression analysis are provided in Table 3. For
QALYs at one year, signiﬁcantly lower QALY scores were esti-
mated for increased baseline age, baseline BMI, and being treated
in the UK. Signiﬁcantly higher QALY scores were estimated for a
higher baseline EQ-5D score. Compared with no treatment,
higher incremental QALY scores were predicted for duloxetine
and for duloxetine plus conservative treatment, and lower (non-
signiﬁcant) QALY scores were predicted for conservative therapy
alone.
For total cost at 1 year, higher costs were predicted for those
women who had previous surgery and those managed by an
urologist compared with a gynecologist. Lower costs were pre-
dicted for women of a higher age, employed, treated in the
United Kingdom or Sweden (compared with Germany), and
treated by a primary care doctor or other health-care provider
(excluding urologist) compared with a gynecologist. Women suf-
fering from stress urinary incontinence alone were also estimated
to incur lower cost compared with those with mixed urinary
incontinence symptoms. No statistically signiﬁcant interactions
between country of residence and treatment cohort for QALYs
and costs were identiﬁed.
Table 4 summarizes the incremental costs and QALYs for
pairwise treatment comparisons based on the multivariate
regression model. It also provides details of the number of leaks
avoided in the last week. Duloxetine alone, duloxetine in com-
bination with conservative treatment, and conservative treat-
ment alone were associated with roughly two fewer leaks per
week compared with no treatment. Duloxetine alone and
duloxetine in combination with conservative treatment for SUI
were associated with incremental QALYs of about 0.03 over a
year compared with no treatment or with conservative treat-
ment alone. Conservative treatment alone did not show an
effect on QALYs. None of the interventions considered
appeared to have statistically signiﬁcant impacts on costs over
a year. No important differences were observed in any outcome
between initiating duloxetine alone and duloxetine in combina-
tion with conservative treatment.
Propensity Scores
With propensity score analysis, no signiﬁcant treatment effects
were estimated in any treatment comparison when the nearest
neighbor approach was employed. The estimates, though, were
consistent with those based on kernel matching and stratiﬁcation
Table 2 Mean (SD) health-care costs and protective materials for urinary incontinence by type of resource used and treatment cohort (£ 2007)*
Cohort
Duloxetine
alone
Duloxetine plus conservative
treatment for SUI
Conservative
treatment for SUI
No treatment
for SUI All
Number of patients* 318 186 545 202 1251
Visits to health-care professional 357 (229) 392 (257) 328 (293) 386 (305) 354 (276)
Diagnostics for UI 199 (324) 149 (232) 126 (271) 202 (388) 160 (303)
Pharmacologic treatments for SUI† 176 (43) 170 (58) 18 (45) 44 (76) 85 (91)
Conservative treatment for SUI 17 (99) 172 (475) 133 (453) 96 (290) 103 (376)
Protective material 74 (120) 68 (74) 68 (75) 81 (99) 72 (92)
All costs 823 (502) 952 (624) 672 (770) 809 (708) 774 (686)
*Only for patients with all available data over the year.
†Duration limited to 365 days.
SUI, stress urinary incontinence; UI, urinary incontinence.
Table 3 Multivariate regression model of costs (£ 2007) and QALYs at
1 year
Estimate (SE)
Part1: QALY at 1 years
EQ 5D index at baseline 0.575 (0.014)†
Age (years) -0.001 (0.0002)†
BMI (kg/m2) -0.002 (0.001)†
Country (United Kingdom) -0.056 (0.009)†
Tx (Duloxetine alone) 0.027 (0.009)†
Tx (Duloxetine plus conservative treatment) 0.025 (0.011)*
Tx (Conservative treatment alone) -0.005 (0.009)
Constant term 0.527 (0.026)†
Part 2:Total cost at 1 years
Previous surgery for SUI 141 (63)*
Age (years) -3 (1)*
Country (United Kingdom; comparator Germany) -236 (74)†
Country (Sweden; comparator Germany) -169 (72)*
Tx (Duloxetine alone) -3 (53)
Tx (Duloxetine plus conservative treatment) 110 (59)
Tx (Conservative treatment alone) -17 (49)
Other health-care provider (comparator:
gynecologist)
-410 (179)*
Primary care doctor (comparator: gynecologist) -278 (72)†
Urologist (comparator: gynecologist) 189 (60)†
Employed (yes) -105 (40)†
SUI alone (comparator mixed UI) -186 (37)†
Constant term 1166 (102)†
*P < 0.05; †P < 0.01.
BMI, body mass index; EQ-5D, EuroQol; QALY, quality-adjusted life-year; SUI, stress urinary
incontinence; UI, urinary incontinence.
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methods. The results based on kernel matching and stratiﬁcation
methods were very similar. Based on their results, although
duloxetine alone and duloxetine in combination with conserva-
tive treatment for SUI seemed to marginally reduce the weekly
number of leaks by about two compared with no treatment,
comparisons of duloxetine (with or without conservative treat-
ment) with conservative treatment alone did not show signiﬁcant
reductions in average number of leaks. Duloxetine (with and
without conservative treatment) consistently but marginally
improved QALYs by about 0.02 to 0.04 (result not statistically
signiﬁcant for “Duloxetine plus conservative treatment” com-
pared with “no treatment for SUI” and when “nearest neighbor”
matching employed) over a year compared with no treatment or
with conservative treatment alone. Conservative treatment alone
did not show an effect on QALYs when compared with no
treatment; neither did it show an effect in combination with
duloxetine when compared with duloxetine alone. None of the
interventions considered appeared to have statistically signiﬁcant
impact on costs over a year. No important differences were
observed in any outcome between duloxetine alone and dulox-
etine in combination with conservative treatment.
Table 5 summarizes the cost-effectiveness results from the
three propensity score matching methods in the form of a series
of pairwise comparisons. The differential costs and QALYs are
presented with the treatment strategy in the row being the refer-
ence (i.e., a positive differential means that treatment has higher
costs or QALYs). The ICER is presented for this strategy in the
ﬁrst column together with the probability that the treatment is
the more cost-effective, assuming a cost-effectiveness threshold of
£20,000 per QALY gained. At NICE’s cost-effectiveness thresh-
old (£20,000 to £30,000 per QALY gained), duloxetine alone
and in combination with conservative therapy were cost-effective
strategies for initial management.
It can be seen that depending on the form of matching,
duloxetine either dominated or had an ICER below £900 per
QALY gained compared with no treatment or with conservative
treatment alone. Duloxetine had a probability of being the more
cost-effective than no treatment and than conservative treatment,
at a £20,000 per QALY threshold, of between 0.86 and 1.00.
Duloxetine plus conservative therapy had an ICER below £5500
compared with no treatment or conservative treatment alone,
and probabilities of being the more cost-effective from 0.68 to
0.99. Duloxetine compared with duloxetine plus conservative
therapy showed very similar outcomes but an additional cost for
the combined intervention; the probability of either strategy
being the most cost-effective was approximately 0.50.
Discussion
The SUIT study provides a rare example of a prospective natu-
ralistic study in the context of stress urinary incontinence in
women. Using a cohort of 1510 patients, the study provided
estimates of 1-year costs and QALYs associated with the use of
duloxetine (with or without conservative therapy), conservative
therapy alone, and no treatment. The statistical modeling pro-
vides estimates of the differential costs and beneﬁts of therapies,
which are more reliable than a crude (unadjusted) comparison of
the groups. The study suggests that in terms of average effects,
duloxetine (with or without conservative therapy) dominated
conservative therapy and no treatment, or had cost per QALY
gained below standard thresholds such as those used by NICE.
Thus, duloxetine, either alone or in combination with conserva-
tive treatment, can be considered a cost-effective treatment for
SUI. Nevertheless, it should be emphasized that the differences
between the therapeutic groups were small, both in terms of costs
and QALYs, over the period of a year.
Although randomized trials offer high internal validity in
assessing the efﬁcacy of interventions, they often fail to provide
reliable evidence on the costs and health effects of particular
interventions, as they are used in routine clinical practice. This is
particularly the case with randomized trials of pharmaceutical
products, which often have short periods of follow-up, focus on
clinical outcomes rather than the impact on patients’ perceived
health, fail to compare with all relevant existing treatments and
take place prior to the widespread use of the product [26]. There
is therefore a potential role for more naturalistic studies, in
addition to RCTs, where measurement of outcomes takes place in
the context of “real-life” clinical management [27]. A systematic
review of the randomized trials, which evaluated duloxetine in
SUI, found a positive impact on HRQoL, subjective cure rates,
and improvement in incontinence, but also a high rate of side
effects [11]. The most troublesome side effect was nausea, which
occurred in up to 25% of subjects, and might be considered to
have potentially adverse effects on HRQoL. The characteristics
of these trials suggests potential value in evidence from SUIT:
relatively short follow-up (mostly 12 weeks, but as little as 3
weeks and no more than 36 weeks); a focus on disease speciﬁc
HRQoL measures rather than generic measures preferred for
cost-effectiveness, and little evidence on the use of duloxetine in
combination with conservative therapy [11]. A Cochrane system-
atic review of the effectiveness of conservative treatment sug-
gested that it leads to about one fewer incontinence episode per
day on average (Hay–Smith, 2006 #8937) (compared with an
estimate of about 1.5 fewer episodes weekly in the current analy-
sis). Nevertheless, the trials in the review were small (25–43
participants), over shorter time periods (8 weeks to 6 months),
and likely involved more systematic training and monitoring.
Nevertheless, naturalistic studies are typically observational in
that they do not randomize patients to interventions. To estimate
the differential effect on costs and beneﬁts of interventions in such
studies, it is necessary to use appropriate techniques to deal with
potential selection bias because of confounding, namely factors
Table 4 Summary of number of leaks avoided per week, incremental QALYs and incremental costs (£ 2007) at 1 year for individual treatment
comparisons
Number of leaks
avoided per week (SE) Incremental QALY (SE) Incremental cost (SE)
Duloxetine vs. No treatment for SUI -2.1 (0.6)† 0.027 (0.009)† -3 (53)
Conservative treatment for SUI vs. No treatment for SUI -1.5 (0.5)† -0.005 (0.009) -17 (49)
Duloxetine plus Conservative treatment for SUI vs. No treatment for SUI -2.3 (0.7)† 0.025 (0.011)* 110 (59)
Duloxetine vs. Duloxetine plus Conservative treatment for SUI 0.2 (0.9) 0.002 (0.015) -113 (79)
Duloxetine vs. Conservative treatment for SUI -0.5 (0.8) 0.031 (0.013)* 14 (72)
Duloxetine plus Conservative treatment for SUI vs. Conservative treatment for SUI -0.7 (0.9) 0.030 (0.014)* 127 (77)
*P < 0.05; †P < 0.01.
QALY, quality-adjusted life-year; SUI, stress urinary incontinence.
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related to treatment selection, which also determine treatment
outcomes. Here, two general methods were employed for this
purpose: multivariate regression and propensity scoring. Multi-
variate regression uses observed patient and health system char-
acteristics to adjust estimates of cost and beneﬁt to allow for
differences in the characteristics of patients undergoing the differ-
ent treatments. Propensity scores take this a step further by
seeking to match patients undergoing different treatments accord-
ing to the likelihood of their receiving a given intervention.
It is important for economic analyses to relate to speciﬁc
jurisdictions in terms of relevant evidence. Rather than present
four separate analyses here (one for each country recruiting into
SUIT), the analysis was undertaken from the viewpoint of the UK
given the availability of suitable cost data and the widespread use
of economic analyses to support decision-making. This analysis
used UK-speciﬁc costs, but resource use and outcome data from
all four countries. The statistical models have sought to adjust for
differences between countries in these measures and no impor-
tant interactions between country and treatment were observed.
Nevertheless, the cost-effectiveness results could vary with unit
costs from other countries.
The study’s limitations should be acknowledged. For the
cost-effectiveness comparison, it was necessary to identify a
cohort to facilitate a meaningful comparison of alternative treat-
ment strategies. In order to identify as homogeneous a group as
possible, a speciﬁc cohort was deﬁned for the analysis, which
included women who were not undergoing any treatment for SUI
at observation 1, and were reported to be undergoing one of the
speciﬁc treatments of interest at observation 2. This process of
cohort identiﬁcation meant that only 1510 out of the 3739
women who participated in SUIT were included in the analysis.
Although this loss of data reduces the precision with which costs
and beneﬁts could be estimated, it is unlikely to increase the
potential for bias. In principle, other interventions could have
been added to the comparison, such as surgical treatment and
other pharmaceuticals. Nevertheless, the numbers of patients
undergoing such treatments who were untreated at observation 1
were too small for reliable estimates of costs and beneﬁts.
Table 5 Incremental QALYs (SE), incremental costs (SE) (£ 2007) and cost-effectiveness for the separate treatment comparisons based on the
propensity scores approach
Compared with:
No treatment for UI Conservative treatment only
Duloxetine plus
conservative treatment
(a) Nearest neighbor matching
Conservative treatment only DQALY = -0.012 (0.022)
DC = -34 (80)
ICER = 2970
P(CE)20,000 = 0.35
Duloxetine treatment only DQALY = 0.026 (0.023)
DC = 21 (85)
ICER = 812
P(CE)20,000 = 0.86
DQALY = 0.032 (0.021)
DC = -99 (113)
ICER = dominant
P(CE)20,000 = 0.91
DQALY = 0.0004 (0.029)
DC = -120 (96)
ICER = dominant
P(CE)20,000 = 0.59
Duloxetine plus conservative DQALY = 0.021 (0.024)
DC = 112 (119)
ICER = 5375
P(CE)20,000 = 0.74
DQALY = 0.015 (0.024)
DC = 56 (170)
ICER = 3852
P(CE)20,000 = 0.68
(b) Kernel matching
Conservative treatment only DQALY = -0.011 (0.013)
DC = -68 (54)
ICER = 6379
P(CE)20,000 = 0.28
Duloxetine treatment only DQALY = 0.029 (0.009)**
DC = -9 (54)
ICER = dominant
P(CE)20,000 = 1.00
DQALY = 0.031 (0.010)**
DC = -40 (61)
ICER = dominant
P(CE)20,000 = 1.00
DQALY = -0.004 (0.016)
DC = -148 (60)*
ICER = dominant
P(CE)20,000 = 0.58
Duloxetine plus conservative DQALY = 0.021 (0.011)
DC = 95 (61)
ICER = 4494
P(CE)20,000 = 0.92
DQALY = 0.029 (0.012)*
DC = 33 (89)
ICER = 1124
P(CE)20,000 = 0.99
(c) Stratiﬁcation method
Conservative treatment only DQALY = -0.012 (0.016)
DC = -70 (60)
ICER = 5775
P(CE)20,000 = 0.29
Duloxetine treatment only DQALY = 0.031 (0.013)*
DC = -7 (55)
ICER = dominant
P(CE)20,000 = 0.99
DQALY = 0.031 (0.012)*
DC = -38 (60)
ICER = dominant
P(CE)20,000 = 0.99
DQALY = -0.005 (0.016)
DC = -129 (60)*
ICER = dominant
P(CE)20,000 = 0.54
Duloxetine plus conservative DQALY = 0.027 (0.017)
DC = 114 (61)
ICER = 4282
P(CE)20,000 = 0.90
DQALY = 0.029 (0.015)*
DC = 40 (83)
ICER = 1363
P(CE)20,000 = 0.96
*P < 0.05; **P < 0.01.
Dominated means the strategy in the ﬁrst column has higher QALYs and lower costs than the comparator strategy. P(CE)20,000 is probability of intervention being cost-effective at a
cost-effectiveness threshold of £20,000/QALY.
DC, incremental cost; ICER, incremental cost-effectiveness ratio; DQALY, incremental quality-adjusted life-year.
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As with most observational studies, missing data was a
feature of the SUIT dataset. This is a particular problem for
economic analysis, because estimates of total costs and QALYs
require the use of outcomes measured at different points of
follow-up. If one of these data points is missing, the whole
cost/QALY estimate is effectively missing. Therefore, it is neces-
sary to impute the missing data. We used a multiple multivariate
imputation technique that implicitly assumes that after condi-
tioning on the covariates, the missing data is missing at random,
and kept covariate selection in the separate imputation models at
a minimum in an attempt to avoid introducing biases. The esti-
mated uncertainty took into account the fact that part of the data
was imputed, and the results following multiple imputation were
in line with those based on available data only (results not
shown), although they on occasions gained statistical signiﬁcance
only after imputation.
Both multivariate regression and propensity score matching
approaches rely on the potential sources of bias (i.e., character-
istics of patients that inﬂuence both treatment selection and
outcomes) being measured in the study and appropriately used as
covariates in the statistical models. While care has been taken in
the development of the multivariate linear regression framework,
this approach is more limited in its abilities to control for con-
founding in the estimation of treatment effects in observational
studies (e.g., although no statistically signiﬁcant interactions
between treatment cohort and covariates were identiﬁed, imbal-
ances might still remain). The propensity scores approach
directly minimizes imbalances between the treatment groups
with respect to the covariates in order to reduce the bias in the
estimation of treatment effects, and therefore is likely more
appropriate for the estimation of cost-effectiveness. Therefore,
while in the present study the estimated treatment effects on
health outcomes and costs from the two approaches are very
close, we summarize cost-effectiveness for the propensity scores
approach only. The use of another statistical technique, instru-
mental variables (IV), can adjust for both observed and unob-
served confounding variables by breaking the link between
treatment choice and outcomes reported [28,29]. The use of IV
was explored in this study, but appropriate instruments (which
predict treatment selection but not outcomes) were not identiﬁed.
A principle of economic evaluation to support decision-
making is that all relevant evidence is included. Ideally, this
would include factoring in the results of randomized trials,
including duloxetine and conservative therapies. Given the het-
erogeneity in these trials, the different outcomes measured,
including the absence of utility data in the trials, and, in the case
of the drugs trials, the selective patient populations, the synthesis
of the trial and SUIT data was considered infeasible. The SUIT
dataset has the advantage of greater generalizability and the
inclusion of the major comparators, but the absence of the trial
data from the analysis should be borne in mind when interpreting
the results.
In conclusion, the SUIT study provides a rare opportunity to
assess the costs, effects, and cost-effectiveness of a pharmaceuti-
cal as used in routine clinical practice in a large number of
patients and against appropriate comparators. Although the limi-
tations of the use of observational data for this purpose need to
be acknowledged, the study suggests that initiating duloxetine
therapy in stress urinary incontinence is a cost-effective treatment
alternative.
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